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Potentially Actionable Targets: Evidence Standards for Credible Next Generation Sequencing 
Technology Assessment Claims 
Paul C. Langley, PhD 
College of Pharmacy, University of Minnesota 
 
Abstract 
Despite considerable resources devoted to developing databases to support competitive credible claims for next generation sequencing 
(NGS) claims, we have yet to meet the standards required in health technology assessment to support such claims. The purpose of this 
commentary is to consider options open in establishing claims for NGS recommendations. Although NGS platforms offer potential 
promise in improving clinical outcomes, supporting cost-effectiveness and reducing the overall cost of care in target populations, this 
has yet to be demonstrated on a scale that is likely to satisfy reimbursers and health care decision makers. Issues addressed include (i) 
the importance of credible, evaluable and replicable claims from individual NGS platforms; (ii) the difficulties in moving beyond broad-
brush claims for improved survival; (iii) the standards required for an NGS evidence base; (iv) protocol designs in establishing the 
independent contribution of NGS actionable therapy recommendations to outcomes claims; (v) the role of NGS registries; and (vi) 
protocols to support ongoing credible, evaluable and replicable claims in target patient populations. The critical issue is not analytical 
and clinical validity but clinical utility. This has yet to be demonstrated.   
 




The last decade has witnessed a flurry of activity in identifying 
potentially actionable targets for therapy choices under the 
umbrella of genomic profiling for next generation sequencing 
(NGS) recommendations. Utilizing genomic profiling, research 
groups and commercial vendors of assay platforms have 
attempted to identify actionable targets for therapy 
interventions, notably in late stage cancer. Irrespective of the 
intrinsic technical merits of competing platforms, their 
analytical and clinical validity, a reimburser will require 
evidence for clinical utility: the ability of the platform to 
improve outcomes, reduce direct medical expenditures and 
provide information regarding the benefits and harms of 
testing 1 . These requirements are no different from those 
expected from any other medical intervention. Reimbursers 
may inquire as to whether or not the various vendors have 
undertaken: randomized clinical trials (RCTs) in target patient 
groups, whether these trials have demonstrated clinically 
meaningful differences in outcomes and adverse event 
profiles, whether claims modeled from such trials have 
generated unbiased credible, evaluable and replicable claims 
and whether these claims have been assessed through 
prospective pragmatic or effectiveness trials, through  
retrospective data or in observational tracking studies. These 
standards for establishing a credible evidence base are not 
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new and have been explored at length in previous 
commentaries in INNOVATIONS in Pharmacy as well as 
providing a focus for version 2 of the proposed Minnesota 
Guidelines for Formulary Evaluations 2 3 4 .  
 
The previous commentaries addressed two issues: first, the 
impact of NGS on drug development, characterized as one of 
creative destruction where the adoption of NGS sets in train 
an incessant program of product and process review as NGS 
platforms evolve; and second, the questions a formulary 
committee should ask in establishing the clinical utility of an 
NGS platform. The overall conclusion from these two 
commentaries is that the NGS evidence base is inadequate. 
There is limited evidence for clinical utility and, unfortunately, 
limited appreciation of the steps required to establish such an 
evidence base. Unless NGS developers are prepared to 
undertake the investments necessary to create such an 
evidence base and to support the ongoing curation of their 
NGS platform, physicians, patients and health care decision 
makers will, understandably, be reluctant to reimburse and 
encourage their introduction into routine clinical practice. 
Simply claiming analytical and clinical validity for an NGS 
platform is not sufficient. the marketplace will require 
substantive evidence for clinical utility in treatment practice. 
 
The purpose of this commentary is explore a number of issues 
that need to be addressed in establishing the evidence base to 
support claims for the clinical utility of individual NGS 
platforms. These issues apply irrespective of whether the NGS 
platform is designed to generate a menu of potential therapy 
targets linked to a genomic mutation assessment or whether 
the platform takes a more targeted approach in identifying 
therapy options or even ‘ideal’ mono- or combination 
therapies.  
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The critical issue is one of scientific credibility: do the claims 
made for NGS platforms meet the standards of normal 
science? Are the claims credible, evaluable and replicable in 
the target patient population? This standard is hardly 
revolutionary; it has been in place since the 17th century and is 
clearly articulated in the motto of the Royal Society (founder 
1660; Royal Charter 1662): Nullius in verba (take no one’s word 
for it) 5.  
 
Reimbursers will ask two questions: (i) are the claims for the 
NGS platform credible, evaluable and replicable; and (ii) are 
claims for the superiority of one assay platform over another, 
not only credible, evaluable and replicable, but does the 
claimed‘ superior’ platform offer advantages that are 
meaningful in the target population? If there is, for example, a 
recommendation for a switch between platforms, can the 
vendor claim that the clinical benefits and harms from 
switching in a target population are worth the possible 
increase in assay costs associated with its adoption in routine 
practice?  
 
In exploring these issues, the underlying theme will be that, 
outside of establishing analytical and clinical validity, the 
evidence base required to address potential reimburser 
concerns for clinical utility is potentially biased and limited in 
its ability to support NGS claims. Both issues have to be 
addressed. The first in terms of the designs of randomized 
clinical trials (RCTs), observational studies and registries, the 
latter in terms of a commitment by NGS vendors to a 
structured program of RCTs and observational studies. 
Whether registries can contribute is an open question.  
 
Failure and Survival 
Physicians investing in an NGS platform to identify potential 
target therapies based on the patient’s genomic profile are, to 
date, typically presented with a menu of ‘benefit’ options for 
the individual patient. In addition, reports sent to the physician 
may also provide information on clinically significant 
alterations, available clinical trials and response markers. As 
well as detailing therapies where the patient may be expected 
to be of potential benefit, a list may also be provided where 
the predicted response is ‘intermediate’ or where no potential 
benefit is expected.  
 
If the claims made for an NGS platform are focused on overall 
measures for a target population such as survival care has to 
be taken to account for failures in therapy recommendations. 
Consider, for example, a recently published claim for matched 
versus unmatched therapies by Herzog et al 6. In this study 
claims for targeted therapies in recurrent epithelial ovarian 
cancer (EOC) taken from the CARIS molecular registry were 
classified as matched as opposed to unmatched. A matched 
claim was defined to include subjects receiving at least one 
treatment associated with predicted benefit and no treatment 
associated with lack of benefit at any time following diagnosis. 
Subjects with an unmatched claim were those not included in 
the benefit cohort (i.e., they received at least one treatment 
associated with a potential lack of benefit). To demonstrate 
the contribution of biomarker profiling the survival profiles of 
the two groups were compared. The study claimed that the 
matched patients experienced a significantly greater 
improvement in overall survival time from molecular profiling 
of 36 months compared to 27 months for the unmatched 
group.  
 
The concern with this approach to establishing claims for 
actionable targets is that subjects who were initially 
introduced to a therapy that had a predicted benefit but who 
subsequently were introduced, either sequentially or in 
combination, to a ‘non-benefit’ therapy were included in the 
unmatched group. A more rigorous assessment approach, 
which would reduce claims for survival benefit from matching 
to benefit therapies, would be to include this group in the 
matched category, recognizing that those who were 
introduced to non-benefit therapies could be considered 
targeted ‘failures’. This would, of course, reduce the claimed 
differences in median survival times while presenting a more 
realistic profile for platform performance in treatment 
practice. 
 
A further issue which should be addressed is whether or not 
individual actionable therapies provided a significant survival 
advantage over each other. In the Herzog et al paper this issue 
could not apparently be addressed because of the relatively 
small sample size. As a result, the claims made were for a 
‘bundle’ of actionable benefit therapies. The potential 
importance of separately identifying actionable therapies had 
been brought out by Kim et al in an earlier paper on predicted 
short-term therapeutic response and long-term survival for, 
again, EOC 7.  A retrospective assessment of predictors for 
targeted response with three standard chemotherapy drugs 
(paclitazel, cyclophosphamide and topotecan) were compared 
in terms of (i) median survival time difference between 
responders and non-responders and (ii) survival outcomes for 
treatment for recurrent disease. The authors reported major 
differences between the three therapies, supporting the 
importance of drilling down to individual therapies.  
 
The potential different ‘survival’ responses to menu items 
judged ‘potentially actionable or beneficial’ raises concerns in 
the design and replication of clinical trial results (and the 
potential for bias in poorly designed trials). First, the need to 
control for the distribution of mutations and the matching of 
‘actionable therapies’ and, second, the need to control for 
physician choice or, more specifically, to address the issue of 
why  physicians select particular menu items and, equally 
importantly, why do physicians reject menu items in their 
choice of therapy? 
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External Validity 
The question of whether or not the results of phase 3 trials 
have external validity has long been of concern. Can claims 
based upon phase 3 trial results, including modeled cost-
outcomes claims, be evaluated and replicated in target patient 
populations? A concern that is further amplified by the 
apparent inability of researchers to replicate phase 3 results 
under identical protocols. The net result is that all too many 
marketing approvals are taken at face value on what latter 
transpires to be a limited and even misleading evidence base. 
This situation is further aggravated by non-evaluable 
technology assessment claims extrapolating from these clinical 
trials. If we apply the standards of normal science, at least in 
respect of modeled cost-outcomes claims, if these cannot be 
evaluated (e.g., lifetime cost-per-QALY claims from groups 
such as the Institute for Clinical and Economic Review) then 
they should be rejected 8. We don’t know whether the claims 
are right or if they are wrong and, in the majority of cases, we 
will never know. 
 
Given these concerns with the classical program of drug 
development and the reliance on two phase 3 placebo 
controlled trials (often producing conflicting results), the task 
facing NGS platform developers is daunting. Are they to 
underwrite a program of phase 3 equivalent RCTs, which is 
both time consuming and expensive, to generate claims within 
target populations, or are they to fall back upon less rigorous 
(probably non-randomized) observational or similar designs to 
expedite time to market? While RCTs may address the issue of 
the distribution of mutations across target populations, where 
the standard of care is referenced against an active ‘potentially 
actionable choices’ arm, the issue of external validity still arises 
as there is no control for physician choice. One answer may be 
to reduce menu choices, but this does not get around the 
question of bias due to non-randomization and the attempt to 
claim for overall survival or other outcome benefits in target 
populations where the mutation distribution may vary. 
 
To add a further level of complexity, there is the question of 
whether claims based upon well conducted RCTs in one target 
population can be taken as evidence for clinical utility for the 
application of the particular NGS platform in other target 
populations?  If  the principal target is oncology, NGS platform 
vendors will have to come to terms with both the number of 
potential oncology targets and the positioning of the NGS 
platform by disease stage in the continuum of care. Guideline 
developers and professional groups may recommend a 
genomic assessment at particular stages of therapy, but on the 
evidence available they are hardly likely to go further in 
recommending a particular platform, let alone how to evaluate 
platform recommendations.  
 
Physician Choice 
Irrespective of whether or not the physician is presented with 
a menu of options or a single option, many will decide to put 
the NGS recommendations to one side for individual patients. 
This may occur for specific patients or the physician may 
decide not to follow the NGS recommendations for many if not 
most patients. To date, there is a dearth of evidence as to why 
a physician may decide to accept or reject NGS 
recommendations. Are there factors, such as comorbidities, 
the presence of polypharmacy, general symptoms of fatigue or 
frailty that may determine other choices? After all, if 
comorbidities such as cardiovascular disease and diabetes are 
present, let alone depression, anxiety, adverse sleep 
experience and the presence of pain, these may override any 
NGS recommendation? At present, NGS recommendations fail 
to take these into account. It is left to the physician to factor 
these elements into treatment choice. 
 
The presence of comorbidities and other potential decision 
variables in treatment choice will not necessarily be addressed 
in randomized clinical trials (RCTs) let alone non-randomized 
observational studies and registries. Assigning patients in an 
RCT to non-NGS informed treatment choice versus an NGS 
treatment arm does not solve the issue of physician choice. 
Where a menu of options is presented in the NGS-arm, RCTs 
would typically overlook the questions of why a specific menu 
selection was made or why a physician failed to select (if 
treatment choice is not ‘forced’ in the NGS arm) the NGS 
recommendation? Forcing an NGS selection may simply 
reduce any claims for external validity.  
 
The potential for bias in protocol design is more worrying in 
the case of non-randomized observational studies and 
registries. If registries, for example, only track patients where 
the physician has accepted an NGS recommendation, claims 
made will lack both the confidence that might attach to 
randomization as well as to the failure to capture outcomes for 
those where the NGS recommendation is put to one side by 
the physician. At the same time, the issues of (i) why a 
particular menu choice was accepted and (ii) why a physician 
may decide not to assess the genomic profile as an input to 
therapy choice are not addressed. It is one thing to compare 
physicians who have accepted/rejected an NGS 
recommendation and another to compare these groups to 
physicians who opted out of an NGS assessment altogether. 
Even if a registry or an observational study captures both 
patients where the physician has accepted/rejected an NGS 
recommendation, the failure to capture non NGS-influenced 
(or driven) treatment choices is a significant limitation on the 
willingness of formulary committees and other health decision 
makers to support NGS evaluations. Indeed, it could be argued 
NGS vendors need to address this question before supporting 
an NGS platform; after all, the belief that a genomic profile 
‘necessarily’ supports choices that yield improved outcomes is 
still an open question. 
 
If claims for first generation sequencing are to be credible, care 
has to be taken to capture and track physician choice. The 
Commentary FORMULARY EVALUATIONS 
 
http://z.umn.edu/INNOVATIONS                            2017, Vol. 8, No. 3, Article 9                            INNOVATIONS in pharmacy   4 
 
physician may accept or reject any of the recommended 
therapies that are considered of likely benefit. Wherever 
possible, however, it is important to record the actual therapy 
choices (whether these are mono- or combination therapy), to 
include appropriate dosing. Unfortunately, this ‘unbundling’ of 
therapy recommendations is often not possible or simply 
ignored in making platform claims in target patient 
populations. This, as noted below, raises concerns over the 
ability to replicate claims for the platform recommendations in 
target treating populations. With physicians free to choose 
from the indicated ‘benefit’ therapies then overall claims for 
survival in the target population will reflect the ‘unknown’ 
distribution of therapy choices by physicians between patients 
in the target population. Attempts to replicate survival claims 
for the platform in comparison target populations will reflect 
an implicit assumption that the ‘matched’ distribution of 
therapies is the same. 
 
Target Population Claims 
Ideally, claims for NGS platforms should be based on target 
patient populations within defined disease types by stage of 
disease. One option is to consider the bundled therapy or 
‘black box’ model where, irrespective of the choices made 
between those therapies linked to gene mutations, subjects 
are classified as having either been initiated to a ‘benefit’ 
therapy or have been initiated to a ‘non’ or ‘indeterminate’ 
benefit therapy. The claims for competing platforms would 
then contrast those who were initially ‘matched’ to those who 
were ‘unmatched’. As described above, this is the approach 
taken in assessing the Caris platform.  
 
A concern with NGS platforms where menus are presented is, 
possibly paradoxically, the flexibility given to the treating 
physician in the choice of therapies from a smorgasbord of 
matched ‘benefit’ options. Given that it would be impractical 
to try to drill down to determine why the physician chose 
specific items from the matched ‘benefit’ therapies, the fact is 
that different benefit combinations (or monotherapy choices) 
are likely to yield difference outcomes.  
 
If overall survival is the primary outcome, then (putting to one 
side other potential confounding factors) the distribution of 
subject survivals will, presumably, reflect the initial therapy 
choice and, if judged appropriate by the treating physician, 
switches to other matched ‘benefit’ options or the 
introduction of ‘indeterminate’ or ‘non-benefit therapies’. 
Claims for overall survival benefit for ‘matched’ versus 
‘unmatched’ therapies will depend, therefore, on the joint 
contribution of (i) isolating the ‘benefit’ therapies and (ii) 
physician initial and subsequent choice involving those benefit 
therapies. We have no idea, unless each therapy combination 
is tracked, whether or not more guidance given to the treating 
physician where matched therapy combinations were ranked 
as more likely to confer benefits, might yield an improved 
survival profile. A situation, it might be noted, that is no 
different from a classical phase 3 RCT where we can claim that, 
overall, introduction of a new product yields an improved 
survival profile but we have little idea why some subjects 
respond better than others. In this case, it would be possible 
to determine responses to selected menu combinations, but 
we would still not know why patients presented with the same 
menu of options responded differently to the same menu 
option choice. 
 
One answer would be to record the outcomes associated with 
each possible therapy combination. this would dilute a specific 
‘bundled’ claim if, as might be anticipated, individual therapy 
combinations from the designated menu yield clinically and 
significantly different outcomes in the target population. 
Given this, reimbursers might be wary of claims that rely on an 
assumption of a given weighted distribution of initial therapy 
choices in the target population with the potential for bias in 
the weights selected. A situation which, as noted, is made 
more opaque by the fact that we may have no idea what 
prompted a physician to choose a particular therapy 
combination. This situation becomes even more troublesome 
if attempts are made to assess competing NGS platforms. 
 
Independent Contribution 
One possibility (albeit remote) would be to consider, within a 
multivariate, as opposed to a descriptive overall survival 
framework, the contribution of physician selection of therapy 
benefit’ recommendations. Rather than the bundled ‘black 
box’ approach, a Cox survival model could be specified where 
specific combinations of therapies from the menu of matched 
therapies are captured as dummy variables and the marginal 
or independent impact evaluated.  
 
Broad-brush claims for outcomes such as median survival 
across cancer types are unlikely to be convincing; a ‘black box 
approach where platforms are compared in terms of gross 
outcome measures rather than on asking the more 
fundamental question: what is the independent contribution 
of NGS-driven ‘actionable therapy choices’ on the clinical, cost-
effective and budget impact outcomes of therapy?  The critical 
issue is to identify, by analogy to classical RCT designs, the 
independent effect of therapy recommendations from 
competing NGS platforms. The fact that an NGS platform 
generates recommendations for actionable therapies is only a 
first step. The critical question is whether or not, in the target 
disease population, a claim for the independent effect of that 
recommendation can be justified; is it credible, evaluable and 
replicable? Irrespective of whether the claim (hypothesis) is 
expressed in purely clinical terms, in terms of overall survival, 
progression free survival, quality adjusted life tears or cost-
per-QALY, the independent contribution of the contribution of 
the actionable target has to be evaluated. This requirement is 
unexceptional. Unfortunately, it is often overlooked.  
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Isolating, for a particular target population the independent 
contribution of  a platform linking drugs to likely actionable 
targets requires, in the first instance, a systematic review of 
the literature in that cancer state or stage of disease, an 
assessment of potential confounding factors and, second, the 
likely quantitative impact of these on treatment outcomes. 
Typically, there is a substantial literature to be evaluated. If the 
outcome of interest is survival than questions that need to be 
addressed would cover the contribution of demographic and 
socio-economic characteristics to survival (e.g., age, gender, 
race, access to care, employment status), the presence of 
comorbidities (e.g., cardiovascular status, diabetes), the 
presence of pain, adverse sleep experience, depression, 
anxiety, somatic status and adverse events (both from the 
target disease state and comorbidity treatment). To these 
should be added compliance with therapy, (including both 
adherence and persistence – and their potential 
determinants). If the outcome of interest is quality adjusted 
life years (QALYs) then, clearly, many of these comorbidities 
will impact quality of life. If resource utilization and costs enter 
the analysis then these need to be identified, costs rather than 
charges captured and, if possible, resources used and costs 
contributed by the target disease separated from those 
resources and costs that are associated with comorbidities. 
Probably of equal importance, if a range of treatment sites are 
contributing, the question of whether the individual treatment 
site might be considered ‘typical’ in its resource utilization and 
cost structure.  
 
A number of potential confounding factors together will 
require decisions as to the choice of patient reporting outcome 
(PRO) instrument or summary measures. If fatigue, for 
example, is considered a potential confounder in qualifying 
outcomes claims then which measure of fatigue is to be used? 
Similar arguments apply to evaluating the impact of 
depression (likelihood of major depressive disorder?), anxiety, 
pain (pain experience in terms of severity and frequency, 
likelihood of chronic pain) and sleep experience. How are 
comorbidities to be captured? Should key comorbidities be 
flagged as dummy variables or should a measure such as the 
Charlson comorbidity index be used?   
 
Survival and Quality of Life 
While broad brush claims for increased overall survival or 
progression free survival following application of NGS guided-
interventions are increasingly made, it is a moot point as to 
whether such claims are meaningful to reimbursers, let alone 
patients and treating physicians 9 . Given the experience in late 
stage cancer therapies including  the impact of competing 
regimens on adverse effect profiles, the likelihood of adverse 
events and factors such as depression and anxiety on 
adherence and persistence, a case can be made that the 
quality of life and quality adjusted life years (QALYs) are more 
meaningful. Rather than taking an easy way out and simply 
comparing survivorship profiles, reimbursers may be more 
interested in competing cost-per-QALY claims.  
 
If this argument is accepted and without necessarily going into 
the issue of cost-per-QALY willingness to pay thresholds for 
NGS pricing negotiations, there is the question of the choice of 
QALY measure. Should a vendor express claims in terms of a 
generic QALY measure (EQ-5D-3L, EQ-5D-5L) or an instrument 
that generates items for a ‘generic’ measure such as the SF-6D  
(SF-36, SF-12), a cancer  or a disease specific measure? In the 
last case there are a number of platforms that have proposed 
cancer-specific measures of quality of life. At the same time 
there are questions to be addressed regarding the 
measurement properties of the instrument (e.g., does the 
instrument have interval scoring properties?). 
 
Establishing and Replicating Claims 
If the independent contribution of an NGS platform is to be 
evaluated then it must be within the framework of a 
multivariate model. The choice of model should capture 
characteristics of the targeted population, the stage of disease, 
the standards for intermediate and final endpoints, the 
required data elements, the timing of data collection and the 
timeframe over which the claim is to be assessed. This is 
elementary.  As noted in earlier commentaries, reimbursers 
should require a protocol to be submitted detailing how the 
claims are to be evaluated. This protocol should be agreed with 
the reimbursers and IRB approval sought. 
 
As it stands, there is a virtual absence of evidence to support 
claims for the clinical benefits and the cost-effectiveness of 
competing NGS platforms in target populations. There have 
been no attempts, as far as can be ascertained, to either 
develop models with evaluable claims and evaluate those 
claims or to report directly from observational studies on the 
cost-effectiveness of competing NGS approaches utilizing 
multivariate modeling. At best, there is one proposal for a RCT 
design to support comparative-effectiveness claims in patients 
with colorectal cancer/polyposis syndromes 10.  
 
The Role of Registries 
Although establishing registries in NGS has become popular, it 
is not clear what the registries are intended to achieve or even 
whether establishing a registry is appropriate given the 
diversity of potential disease states and stage of disease and 
the choice of actionable targets. Unfortunately, evidence on 
the structure of the proposed registries, the specification of 
data inputs and the timing of data collection is unclear. From 
the descriptions presented, it is also not clear what the 
contribution from patients is expected to be. As detailed, in the 
discussion above of the need to capture potentially 
confounding factors in evaluating the independent 
contribution of actionable therapy choice to outcomes, patient 
inputs may play a critical role in claims assessment; let alone 
an assessment of why physicians make particular choices. 
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A patient registry is only relevant if it is appropriately 
managed, capturing the minimum data points and number of 
subjects necessary to support a multivariate assessment of the 
impact of targeted therapies. As noted, the structure and 
content of the registry should be justified in terms of the 
registry target patient populations and the ability of the 
registry to avoid claims of bias. A blanket commitment to a 
registry without justifying the design and content of the 
registry in terms of the target populations and claims to be 
assessed within those target populations should be avoided. 
The registry should report on the protocols for the target 
patient populations identifying the primary and secondary 
endpoints, number of subjects to be recruited and associated 
power calculations. In cancer, for example, one size of study 
design does not fit all. A ‘lean’ registry which focuses on 
claimed common outcomes (e.g., overall survival) is unlikely to 
capture the data points necessary to validate health 
technology assessment claims.  
 
Questions should also be raised as to the projected ‘size’ of the 
registry, the anticipated recruitment of subjects and the 
timeframe within which claims assessments are to be 
reported. Is the registry designed to capture physicians who 
have requested a genetic profile but who fail to follow through 
on the recommendations? Are these physicians tracked as a 
control group? A further issue concerns the ‘bundling’ as 
opposed to the tracking of specific therapy interventions. If 
physicians have the option of choosing between therapies 
identified as actionable, are these individual therapies to be 
tracked? If so, is the registry designed to capture the required 
subject size for hypothesis testing with these specific drugs? 
 
As noted above, claims for NGS actionable predictions should 
not only be compared across therapy platforms but, following 
the standard RCT designs, against a control group for these 
actionable therapies. It seems somewhat pointless to develop 
a registry that only reports on the outcomes for physicians who 
had requested a genetic profile and who may or who may not 
have acted upon the recommendations for therapy choice. 
Should account be taken of physicians who have not requested 
an NGS assessment? Does their absence imply any bias in the 
results claimed? What do we know, as discussed above, 
regarding the factors that influence whether or not a physician 
requests an NGS assessment in the first place? 
 
At the same time, although this possibility can only be touched 
on here, there are a large number of cancer registries including 
state and regional registries as well as private registries in the 
US.  Rather than reimbursers asking NGS vendors, as part of 
their market entry strategy, to propose establishing a registry 
for their product, there is the option of either working with 
specific cancer registries to record NGS requests and adoptions 
or to utilize these registries to establish benchmarks 11. 
Conclusions 
If claims for NGS platforms are to be considered in formulary 
decisions and, equally importantly, accepted by patients and 
treating physicians, then the claims made must be, for the 
target populations, credible, evaluable and replicable claims. 
Unfortunately, previous commentaries in this series have 
pointed out that health technology assessments over the past 
30 years have shown a dogged commitment to building 
models to support cost-effectiveness and cost-utility claims 
that are unevaluable 12. Particularly egregious are lifetime 
cost-per-QALY claims that clearly fail the standards of normal 
science. Unfortunately, there is growing evidence of the 
difficulty of weaning manufacturers and consultants off 
pseudoscientific modeled claims, as seen for example in the 
recent Li et al study that models the cost-effectiveness of an 
NGS panel of 34 cancer-associated genes in metastatic 
melanoma and similar modeled studies in BRCA1 and BRCA2 
testing for ovarian cancer and breast cancer 13 14 15. 
 
Unless vendors are prepared to invest resources in establishing 
a viable evidence base that meets the standards of normal 
science, there must be concerns as to whether the vaunted 
claims and expectations for precision medicine and NGS will be 
realized. Establishing analytical and clinical validity is the easy 
part; establishing clinical utility is by orders of magnitude more 
difficult. Understandably, investors may be reluctant to 
underwrite a vendor’s program of randomized and 
observational studies given the uncertainties not only in 
respect of comparative platform performance but the 
reluctance of health systems and professional groups to adopt 
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